Evaxion A/S American Depositary Share (EVAX)

Price$3.55

Value ScoreC

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-48.11%

Price vs S&P 500 (4W)-18.19%

VGM Score69.13

Market Capitalization$32.28M

All Metrics

Book Value / Share (Quarterly)$0.02

P/TBV (Annual)4.96x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.04

Price vs S&P 500 (YTD)-33.73%

Net Profit Margin (TTM)-50.24%

EPS (TTM)$-0.02

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-0.02

EPS (Annual)$-0.02

ROI (Annual)-31.40%

Cash / Share (Quarterly)$0.05

Revenue Growth QoQ (YoY)148.33%

ROA (Last FY)-27.13%

Revenue Growth TTM (YoY)128.64%

EBITD / Share (TTM)$-0.01

ROE (5Y Avg)-146.57%

Operating Margin (TTM)-69.77%

Cash Flow / Share (Annual)$-0.18

P/B Ratio1.89x

P/B Ratio (Quarterly)1.77x

Net Income / Employee (Annual)$-167,500

EV / Revenue (TTM)5.21x

Net Interest Coverage (TTM)-3.42x

ROA (TTM)-48.75%

EPS Incl Extra (Annual)$-0.02

Current Ratio (Annual)5.85x

Quick Ratio (Quarterly)5.66x

3-Month Avg Trading Volume0.04M

52-Week Price Return37.60%

Revenue / Employee (TTM)$163,700

Tangible BV / Share (Quarterly)$0.34

P/S Ratio (Annual)4.29x

Asset Turnover (Annual)0.27x

52-Week High$12.15

EPS Excl Extra (Annual)$-0.02

CapEx CAGR (5Y)-43.07%

26-Week Price Return-40.19%

Quick Ratio (Annual)5.70x

13-Week Price Return4.41%

Total Debt / Equity (Annual)0.44x

Current Ratio (Quarterly)5.85x

Enterprise Value$16.55M

Asset Turnover (TTM)0.19x

Revenue / Employee (Annual)$163,700

Pretax Margin (Annual)-114.44%

Cash / Share (Annual)$0.08

3-Month Return Std Dev75.12%

Net Income / Employee (TTM)$-212,200

ROE (Last FY)-45.23%

Net Interest Coverage (Annual)-1.78x

EPS Basic Excl Extra (Annual)$-0.02

Total Debt / Equity (Quarterly)0.44x

EPS Incl Extra (TTM)$-0.02

ROI (TTM)-71.05%

P/S Ratio (TTM)4.22x

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.34

Price vs S&P 500 (52W)13.23%

Year-to-Date Return-25.58%

5-Day Price Return-8.97%

EPS Normalized (Annual)$-0.02

ROA (5Y Avg)-89.94%

Net Profit Margin (Annual)-102.38%

Month-to-Date Return-11.25%

EBITD / Share (Annual)$-0.02

Operating Margin (Annual)-88.55%

LT Debt / Equity (Annual)0.31x

ROI (5Y Avg)-111.21%

LT Debt / Equity (Quarterly)0.31x

EPS Basic Excl Extra (TTM)$-0.02

P/TBV (Quarterly)4.96x

P/B Ratio (Annual)1.77x

Pretax Margin (TTM)-59.78%

Book Value / Share (Annual)$0.34

Price vs S&P 500 (13W)-3.84%

Beta0.28x

Revenue / Share (TTM)$0.02

ROE (TTM)-111.18%

52-Week Low$2.07

vGradeC

gGradeA

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.50est. -0.31

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.10

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
EVAXEvaxion A/S American Depositary Share	C	A	B	$3.55
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Evaxion is a clinical-stage TechBio company developing personalized cancer vaccines and vaccines for infectious diseases using its proprietary AI-Immunology platform. The AI-driven platform decodes the immune system to identify novel vaccine candidates for cancer and bacterial/viral diseases with high unmet medical needs. With candidates advancing through clinical development, Evaxion aims to transform patient outcomes through targeted therapeutic innovations.